Gilead Sciences, Inc. has received a complete response letter (CRL) from the US Food and Drug Administration for filgotinib, its blockbuster prospect for rheumatoid arthritis, because of safety concerns.
The FDA has requested data from two pending clinical studies, MANTA and MANTA-RAy before completing its review of the drug,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?